Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 3.53 B

Share Price

USD 37.35

Avg Daily Volume

934,614

Change (1 day)

1.88%

Change (1 year)

-0.19%

Change (YTD)

-11.22%

Ultragenyx Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -389.94 M

Ultragenyx Pharmaceutical Inc. Operating Cash Flow is USD -389.94 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -23.34% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Ultragenyx Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -508.67 M, a 21.17% change year over year.
Ultragenyx Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -419.81 M, a 41.41% change year over year.
Ultragenyx Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -296.87 M, a 51.15% change year over year.
Ultragenyx Pharmaceutical Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -196.41 M, a -43.03% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: RARE

Ultragenyx Pharmaceutical Inc.

CEO	Dr. Emil D. Kakkis M.D., Ph.D.
IPO Date	Jan. 31, 2014
Location	United States
Headquarters	60 Leveroni Court
Employees	1,294
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.